PUBLICATION

Superior neurometabolic protection by 8-hydroxy-dihydromyricetin over dihydromyricetin in diabetic zebrafish: insights from integrated metabolomics and transcriptomics

Authors
Cheng, Y., Ang, B., Ma, D., Li, Z., Wang, Z., Chen, Q., Zeng, M., Chen, J., Chen, C., Yang, Y., Adhikari, B., Yin, L., Wang, T., He, Z.
ID
ZDB-PUB-250829-12
Date
2025
Source
Food & function   16: 7104-7119 (Journal)
Registered Authors
Keywords
none
MeSH Terms
  • Animals
  • Diabetes Mellitus, Experimental*/drug therapy
  • Diabetes Mellitus, Experimental*/metabolism
  • Flavonols*/chemistry
  • Flavonols*/pharmacology
  • Gene Expression Profiling
  • Metabolomics
  • Oxidative Stress/drug effects
  • Transcriptome/drug effects
  • Zebrafish
PubMed
40878641 Full text @ Food Funct
Abstract
Herein, the effects of C-8 hydroxylation on the protective properties of dihydromyricetin (DHM) in a zebrafish larval model of diabetes and neurometabolic dysfunction were investigated. Diabetes was induced using alloxan and glucose, followed by treatment with DHM and its hydroxylated form, 8-hydroxy-dihydromyricetin (H-DHM), obtained through Beauveria bassiana fermentation. Biochemical, metabolomic, and transcriptomic analyses were conducted to evaluate their differences in efficacy. The results demonstrated that hydroxylation enhanced DHM's ability to improve locomotor activity, regulate Na+/K+-ATPase, Ca2+-ATPase, acetylcholinesterase, glutamate, and ATP levels, and modulate oxidative stress, as well as glucose and lipid homeostasis in diabetic zebrafish. Metabolomic analysis revealed that both DHM and H-DHM influenced key metabolic pathways, including amino acid metabolism, purine metabolism, and glycerophospholipid metabolism, while H-DHM specifically regulated sphingolipid metabolism. Transcriptomic analysis and weighted gene co-expression network analysis (WGCNA) further indicated that hydroxylation enhanced DHM's ability to target genes associated with pancreatic β-cell function, oxidative stress, and energy metabolism, such as DUSP26, ITLN1, gdf11, insl5a, pik3r5, gck, kcnj1a.6, tfr2, ebi3, KYAT3, and hdac12. The enhancement of DHM's regulatory effects on diabetes-associated neurometabolic dysfunction highlights the potential of fermentation-derived natural product derivatives for chronic disease management.
Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping